StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)

Close on Nov 17, 2026Market cap $109.97MP/E –Yield –

LENZ Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

LENZ Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$113.91M. For fiscal 2025 it was -$69.17M. The highest annual figure on record is -$8.72M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$69.17M–
FY2024Dec 31, 2024-$59.39M–
FY2023Dec 31, 2023-$60.38M–
FY2022Dec 31, 2022-$87.98M–
FY2021Dec 31, 2021-$52.85M–
FY2020Dec 31, 2020-$8.72M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$38.71M–
Q1 FY2026Mar 31, 2026-$33.58M–
Q4 FY2025Dec 31, 2025-$33.03M–
Q3 FY2025Sep 30, 2025-$8.59M–
Q2 FY2025Jun 30, 2025-$11.51M–
Q1 FY2025Mar 31, 2025-$16.05M–
Q4 FY2024Dec 31, 2024-$9.08M–
Q3 FY2024Sep 30, 2024-$10.58M–
Q2 FY2024Jun 30, 2024-$15.80M–
Q1 FY2024Mar 31, 2024-$23.94M–
Q4 FY2023Dec 31, 2023-$20.97M–
Q3 FY2023Sep 30, 2023-$13.09M–
Q2 FY2023Jun 30, 2023-$13.52M–
Q1 FY2023Mar 31, 2023-$12.80M–
Q4 FY2022Dec 31, 2022-$22.43M–
Q3 FY2022Sep 30, 2022-$22.22M–
Q2 FY2022Jun 30, 2022-$22.09M–
Q1 FY2022Mar 31, 2022-$21.24M–
Q4 FY2021Dec 31, 2021-$15.59M–
Q3 FY2021Sep 30, 2021-$15.42M–
Q2 FY2021Jun 30, 2021-$13.78M–
Q1 FY2021Mar 31, 2021-$8.06M–
Q4 FY2020Dec 31, 2020-$5.27M–
Q3 FY2020Sep 30, 2020-$2.49M–

More LENZ Therapeutics figures

See a number that looks wrong?